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Purpose: α-fetoprotein (AFP)-producing gastric cancer is a rare tumor with high rates of liver metastasis and a poor prognosis. Many 
studies have been performed but there have been no comprehensive investigations of the clinicopathological and prognosis.
Materials and Methods: Six hundred ninety four patients with gastric cancer who underwent a curative gastric resection in Hanyang 
University Hospital from February 2001 to December 2008 were evaluated retrospectively after excluding active or chronic hepatits, 
liver cirrhosis and preoperative distant metastasis. Among them, thirty five patients had an elevated serum level of AFP (>7 ng/ml) pre-
operatively. The clinicopathological features of AFP-producing gastric cancer were analyzed.
Results: There was poorer differentiation, a higher incidence of lymph node metastasis, more marked lymphatic and vascular invasion in 
the AFP-positive group than in the AFP-negative group. The 5-year survival rate of the AFP-positive group was significantly poorer than 
that in the AFP-negative group (66% vs. 80%, P=0.002). A significantly higher incidence of liver metastasis was observed in the AFP-
positive group than in the AFP-negative group (14.3% vs. 3.6%, P=0.002) with a shorter median time period from the operation to the 
metachronous liver metastasis (3.7 months vs. 14.1 months, P=0.043). Multivariate survival analysis revealed the depth of invasion, 
degree of lymph node metastasis and AFP-positivity to be the independent prognostic factors.
Conclusions: AFP-producing gastric cancers have an aggressive behavior with a high metastatic potential to the liver. In addition, their 
clinicopathological features are quite different from the more common AFP-negative gastric cancer.
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Introduction
Alpha-fetoprotein (AFP) was initially found in the human fetus 
and is normally produced in the fetal liver and yolk sac.(1) The 
elevation of serum AFP level is often considered as abnormal in 
adults, and in clinical practice, AFP is a well-known tumor marker 
for screening or monitoring hepatocellular carcinoma and yolk sac 
tumor. Some studies showed that AFP could be produced in other 
cancers including primary gastric carcinoma.(2) 
A case of AFP-producing gastric cancer with liver metasta-
sis was first reported in 1970. Since then, scattered cases of early 
and advanced AFP-producing gastric cancer have been reported, 
some of them showing poor prognosis with lymphatic and venous 
microinvasion along with high rates of liver metastasis, of both 
synchronous and metachronous types.(3-5) Furthermore, AFP-
producing gastric cancer showed significantly poorer survival than 
the AFP-negative group.(6) It is reported that AFP-producing gas-
tric cancer often has high proliferative activity, weak apoptosis and 
rich neovascularization, as compared with AFP-negative gastric 
cancer.(7) Recently, others have also reported the aggressiveness 
of AFP-producing gastric cancer after observing frequent c-Met 
overexpression in AFP-producing gastric cancer, as compared with 
stage-matched gastric cancer not producing AFP.(8) 
All these studies reflect the aggressive clinical behavior of AFP-
producing gastric cancer, which isconsidered as a special subtype 
of gastric cancer. However, most of these studies were case reports, 
and there were few reports concerning the clinicopathological or 
prognosis of AFP-producing gastric cancer. These issues are clari-
Copyright © 2011 by The Korean Gastric Cancer Association www.jgc-online.orgChun HA and Kwon SJ
24
fied here, especially with respect to the characteristics of liver me-
tastasis. 
Materials and Methods
In this study, 694 patients with histologically confirmed primary 
gastric cancer who underwent curative gastric resection with D2 or 
more extended lymph node dissection at Hanyang University Hospital 
from February 2001 to December 2008 were selected and evaluated 
retrospectively. A total of 25 patients with active or chronic hepatitis 
and liver cirrhosis, as well as 30 patients with preoperative distant me-
tastasis, were excluded from this study (Fig. 1). Preoperative serum 
AFP levels were measured in all patients during the week before 
surgery, using the electrochemiluminance immunoassay (ECLIA) 
method with Cobas
TM immunoassay analyzers (Roche Diagnostics 
GmbH, D-68298 Mannheim). Serum AFP level above 7 ng/ml 
was defined as AFP-positive according to the manufacturer’s in-
structions. There were 35 patients with elevated serum level of AFP 
preoperatively, with a median follow up period of 37.7 months. 
Before the operation, all patients routinely underwent esopha-
gogastroduodenoscopy and abdominal computed tomography in 
order to evaluate tumor location, size and depth, as well as the 
status of lymph node and distant metastasis. Postoperative follow 
up was done with routine blood tests, tumor marker tests and the 
diagnostic tools mentioned above, every 3 months for the first 2 
years and every 6 months thereafter until 5 years postoperatively. 
The diagnosis of postoperative recurrence was performed using 
abdominal ultrasonography or abdominal computed tomography. If 
these examinations did not confirm recurrence, histological biopsy 
or Positron Emission Tomography-Computed Tomography (PET-
CT) were also performed.
Node status and disease stage were reassessed according to the 
UICC TNM classification (6th edition),(9) and surgicopathological 
findings were recorded according to the Borrmann, Lauren and 
WHO International Histological Classification (1997).
Median values were used as the measured values of continuous 
variables, according to the standard distribution. The survival rates 
were analyzed using the Life table or Kaplan-Meier method, de-
pending on the size of the patient group. Differences were exam-
ined with Gehan’s Wilcoxon or the log-rank test, respectively. A 
multivariate analysis of the prognostic factors was evaluated using 
the Cox proportional hazards model (forward stepwise method). 
Analysis was performed with the use of SPSS software version 18.0 
(SPSS, Inc., Chicago, IL). P-values less than 0.05 were considered 
statistically significant.
Results
1. Preoperative serum AFP level
The median value of preoperative serum AFP level was 2.3 ng/
Fig. 1. Patients selection.
Fig. 2. Relationship between preoperative serum AFP level and N 
stage. Th   ere was a signifi  cant increase of median serum AFP level ac-
cording to each N stage (2.3 vs. 2.4 vs. 2.7 vs. 3.4, P=0.001). AFP = 
alpha-fetoprotein.
Fig. 3. Relationship between preoperative serum AFP level and liver 
metastasis. Th   ere was a signifi  cant increase of median AFP level in liver 
metastasis positive group compared to liver metastasis negative group 
(6.5 vs. 2.3, P=0.000). AFP = alpha-fetoprotein.AFP Producing Gastric Cancer
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ml (range, 0.1~1210.0). An increase of AFP level according to 
each pathological N stage was observed along with higher AFP 
levels in hepatic metastasis patients as compared to those in patients 
withnon-hepatic metastasis (Fig. 2, 3).
2. Clinicopathological features according to AFP po-
sitivity
Clinicopathological characteristics were comparatively analyzed 
by dividing samples into AFP-positive and AFP-negative groups 
(Table 1). In histological classification, a poorer differentiation was 
observed more frequently in the AFP-positive group as compared 
with the AFP-negative group. There was a higher incidence of 
lymph node metastasis and a more marked lymphatic and vascular 
invasion in the AFP-positive group compared with AFP-negative 
group. With regard to the depth of invasion, high incidence of AFP 
positivity was observed in T4 patients (26.7%) without a gradual 
increase according to the depth of invasion. A significant difference 
was observed only with the TNM stage. No significant correlation 
was found according to age, gender, Borrmann classification, Lau-
ren classification, extent of resection, tumor location, tumor size, 
neural invasion or recurrence.
Table 1. Clinicopathological fi  ndings of AFP-positive gastric cancer 
in comparison to AFP-negative gastric cancer
AFP-positive AFP-negative  P-value
No. of patients 35  659
Age (yr)* 63   59 0.306
Gender 0.693
  Male 23  454 
  Female 12  205
Gross type 0.895
  Borrmann type 1   1    35 
  Borrmann type 2 19  337
  Borrmann type 3 14 259
  Borrmann type 4   1    28
Lauren classifi  cation 0.545
  Intestinal 15 343 
  Diff  use 15  261
  Mixed   5    54 
    Unknown  0    1 
Histological type 0.019
  WEL   2    66 
  MOD 12  253
  POR 17  170 
  Others   4  170 
Operation method 0.662
  Subtotal gastrectomy 29 526 
  Total gastrectomy   6  133
Tumor location 0.469
  Upper 1/3   4    86 
  Middle 1/3 15  351
  Lower 1/3 16  218
  Whole stomach   0      4
Depth of invasion 0.001
  T1 15  354 
  T2 12  173 
  T3   4  121 
  T4   4    11 
Lymph node status 0.003
  N0 13  388 
  N1   8  148 
  N2   4    58 
  N3 10    65 
AFP-positive AFP-negative  P-value
Stage
† 0.017
  I 16 420 
  II 10   75 
  III   4   91 
  IV   5   73 
Tumor size (cm)*      4.0         3.5 0.725
Lymphatic invasion 0.023
  Negative  11  337 
  Positive 24  322 
Vessel invasion 0.002
  Negative  27  607 
  Positive   8   52 
Nerve invasion 0.193
  Negative  29  429
  Positive 16  230
Recurrence 0.058
  Negative 25  552 
  Positive 10  107 
AFP = alpha-fetoprotein; WEL = well diff  erentiated tubular adenocar-
cinoma; MOD = moderately diff  erentiated tubular adenocarcinoma; 
POR = poorly diff  erentiated tubular adenocarcinoma. *Median value;   
†UICC TNM staging system (6
th ed).
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3. Univariate survival analysis according to clinico-
pathological factors
The 5-year survival rate differed in association with the Bor-
rmann classification, Lauren classification, histological classification, 
extent of resection, tumor location, depth of invasion, lymph node 
metastasis, TNM stage, lymphatic invasion, vessel invasion, neural 
invasion and AFP positivity, but not with gender (Table 2). The 
5-year survival rate of the AFP-positive group was significantly 
poorer than that of the AFP-negative group. In gastric cancer with 
liver metastasis, the AFP-positive group also had a significantly 
poorer 5-year survival rate compared to the AFP-negative group 
Table 2. Univariate survival analysis according to clinicopathological 
factors
Variables (No.) 5-year survival rate (%) P-value
Gender 0.746
  Male (477) 81
  Female (217) 77
Gross type 0.000
  Borrmann type 1 (36) 91
  Borrmann type 2 (356) 89
  Borrmann type 3 (273) 71
  Borrmann type 4 (29) 40
Lauren classifi  cation 0.018
  Intestinal (358) 85
  Diff  use (276) 74
  Mixed (59) 72
  Unknown (1)   0
Histological type 0.000
  WEL (68) 97
  MOD (265) 82
  POR (187) 69
  Others (174) 80
Operation method 0.000
  Subtotal gastrectomy (555) 83
  Total gastrectomy (139) 65
Tumor location 0.000
  Upper 1/3 (90) 67
  Middle 1/3 (366) 82
  Lower 1/3 (234) 84
  Whole stomach (4)   0
Depth of invasion 0.000
  T1 (369) 93
  T2 (185) 82
  T3 (125) 55
  T4 (15) 44
Lymph node status 0.000
  N0 (401) 94
  N1 (156) 76
  N2 (62) 53
  N3 (75) 38
Variables (No.) 5-year survival rate (%) P-value
Stage* 0.000
  I (436) 94
  II (85) 82
  III (95) 53
  IV (78) 36
Lymphatic invasion 0.000
  Negative (348) 94
  Positive (346) 65
Vessel invasion 0.000
  Negative (634) 83
  Positive (60) 48
Nerve invasion 0.000
  Negative (448) 90
  Positive (246) 61
AFP 0.002
  Negative (659) 80
  Positive (35) 66
No. = number; WEL = well differentiated tubular adenocarcinoma; 
MOD = moderately differentiated tubular adenocarcinoma; POR = poorly 
diff  erentiated tubular adenocar  cinoma; AFP = alpha-fetoprotein.
 *UICC 
TNM staging system (6
th ed).
Table 2. Continued
Fig. 4. Overall survival curves of gastric cancer patients with liver 
metastasis according to AFP-positivity (5-year survival rate 20% vs. 
0%, median survival time 26.4 months vs. 11.4 months). AFP = alpha-
fetoprotein.AFP Producing Gastric Cancer
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(Fig. 4).
4. Liver metastasis
We observed a higher incidence of liver metastasis in the AFP-
positive group compared with the AFP-negative group (14.3% vs. 
3.6%), along with a higher incidence of multiple liver metastases 
rather than solitary liver metastasis (60% vs. 16.7%) (Table 3).
The time period from the operation to metachronous liver me-
tastasis was significantly shorter in the AFP-positive group than in 
the negative group. Furthermore, thesurvival time from the point 
of liver metastasis diagnosis revealed significantly shorter survival 
time in the AFP-positive group compared with the AFP-negative 
group.
All 5 AFP-positive liver metastasis patients died within 14 
months, while AFP-negative liver metastasis patients survived as 
long as 75 months. There were no liver metastatic patients who 
had curative liver resection in our facility, but 3 patients underwent 
transarterial chemoembolization, 4 patients received radiofrequency 
thermoablation therapy, and the rest of the patients underwent sys-
temic chemotherapy. No patients other than those in the systemic 
chemotherapy group survived more than 1 year.
There was no significant correlation between AFP positivity 
and the location of recurrence except for liver metastasis (which 
included overlapped metastasis), as shown in Table 4.
5. Multivariate survival analysis according to clini-
copathological factors
As there is a possibility of mutual correlation between significant 
variables observed in univariate survival analysis, the TNM stage 
was excluded initially and when the rest of the significant variables 
were added to the Cox proportional hazard models. Significant 
prognostic factors included the following: depth of invasion, lymph 
node metastasis and AFP, as shown in Table 5. Multivariate analy-
sis limited to gastric cancer patients with liver metastasis revealed 
that AFP and lymphatic invasion were independent prognostic fac-
Table 3. Characteristics of liver metastasis according to the positivity of AFP in gastric cancers
AFP-positive (n=35) AFP-negative (n=659) P-value
Liver metastasis 0.002
  Negative 30  635 
  Positive   5    24 
Number of liver metastasis  0.039
  Solitary   2    20 
  Multiple   3     4 
Interval of metachronous metastasis (months)*
,†      3.7      14.1 0.043
Survival time aft  er metachronous metastasis (months)
†      3.6      11.4 0.041
AFP = alpha-fetoprotein. *Time period from the operation to metachronous liver metastasis; 
†Median value. 
Table 4. Comparison of the recurrence site according to the 
positivity of AFP in gastric cancers
Recurrence* AFP-positive AFP-negative P-value
LR recurrence 1  11  0.465
Liver metastasis 5  24  0.002
PS 5 60  0.305
LN metastasis  4  27  0.064
Others 1 30  0.636
AFP = alpha-fetoprotein; LR = loco-regional; PS = peritoneal seeding; 
LN = lymph node. *Recurrence site includes overlapped metastasis.
Table 5. Independent prognostic factors in multivariate analysis by 
the Cox proportional hazards model
 HR
95% CI
P-value
Lower Upper
T factor T1  
 T2 1.398 0.700 2.794 0.343
 T3 2.652 1.302 5.402 0.007
 T4 3.202 1.245 8.236 0.016
N factor  N0  
   N1 2.050 1.014 4.143 0.046
   N2 3.426 1.595 7.358 0.002
   N3 3.660 1.722 7.781 0.001
AFP 2.699 1.354 5.382 0.005
HR= hazard ratio; 95% CI = 95 percent confidence interval; AFP = 
alpha-fetoprotein.Chun HA and Kwon SJ
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tors, as shown in Table 6.
Discussion
AFP was first identified in the human fetus in 1956.(1) It is an 
albumin-like glycoprotein with a molecular weight of 70,000 dal-
tons. AFP is formed in the yolk sac, non-differentiated liver cells, 
and the fetal gastrointestinal tract and is synthesized as early as 6 
months of gestation to birth.(10) Elevation of the serum AFP level 
at more than 1 year of age implies hepatocellular carcinoma or yolk 
sac tumor. Notably, 70~95% of primary hepatocellular carcinoma 
patients have elevated AFP levels.(11) Although AFP is a useful 
marker for predicting survival and for screening or monitoring in 
hepatocellular carcinoma, its correlation with other tumors remains 
to be clarified. However, some studies showed production of AFP in 
gastrointestinal tracts such as gastric cancers along with rectal can-
cers, gallbladder cancers, lung cancers and bladder cancers.(12-16) 
An elevation of AFP level can also be seen when damaged liver 
cells regenerate, as in alcoholics, individuals with chronic liver cir-
rhosis and HBsAg-carrier patients. It is important to exclude these 
patients from the study, in order to eliminate selection bias.(17)
Pre- and postoperative chemotherapy can affect survival analy-
sis. In order to eliminate the bias from survival analysis, pre- and 
postoperative chemotherapy must be fully considered. Unfortu-
nately, diverse chemotherapy strategies and differing treatment 
times were applied to each one of our patients. Considering che-
motherapy as an analysis factor created a barrier to precise survival 
analysis. Therefore, chemotherapy was excluded as an analysis fac-
tor in our study.
The prevalence of AFP-producing gastric cancer is reported 
to be 6.2~6.3%(18,19) in Korea, 1.3~5% in Japan,(20,21) 2.5% in 
China(22) and 15% in the United States.(23) The discrepancies in 
prevalence might be due to the different methods used to measure 
serum AFP level or may represent regional or racial differences. 
Korean studies usually measured AFP level in patient serum, while 
studies from other countries used immunohistochemical evalua-
tion. One study reported that 104 of 111 (93.7%) of patients with 
preoperatively elevated serum AFP level were proven to be carri-
ers of AFP-producing gastric cancer by immunohistochemistry, 
a proportion identical to that of other studies. This implies that the 
serum AFP level is quite precise and more useful than immunohis-
tochemistry, considering its cost-effectiveness and conveniencex.
(20,21) We observed an incidence of AFP-positive gastric cancer of 
5.0%, which is similar to previously reported values.
The prognosis of AFP-producing gastric cancer is reported to 
be poor. One study reported that the 1-, 3- and 5-year survival 
rates of AFP-producing gastric cancer were 53%, 35% and 28%, 
respectively.(22) Another reported the 5-year survival rate of AFP-
positive gastric cancer to be 28.4%.(21) In Korea, a study of 812 
cases of gastric cancer revealed a 5-year survival rate of 46.6% 
in the AFP-positive gastric cancer group.(18) Our study reported 
a 5-year survival rate of 66%, with a median survival time of 72 
months, which is relatively high compared to other reports.
Liver metastasis, in particular, is a very important prognostic 
factor in controlling AFP-positive gastric cancer because 14.3% of 
the AFP-positive group in our study consequently developed liver 
metastasis. The tendency to exhibit multiple liver metastases was 
high in the AFP-positive group with a significantly shorter time 
period from operation to metachronous liver metastasis as previ-
ously mentioned. These observations indicate that AFP-producing 
gastric cancer has clinical biological behavior that differs drastically 
from that of the AFP-negative group. For some reason, the liver 
may be an environment conduciveto the proliferation of this type 
of cancer. Metachronous second primary tumor was defined as 
when the new primary cancer was diagnosed after 2 months of the 
original primary cancer, based on criteria used by the SEER Pro-
gramme of the National Cancer Institute in the USA.
How can we explain this aggressive clinical behavior of AFP-
producing gastric cancer? Unfortunately, the exact molecular 
mechanism that could explain this is still unclear and far limited. 
Generally, AFP-producing gastric cancer is associated with higher 
proliferative activity, weaker apoptosis and richer neovasculariza-
tion. Some authors suggested that high levels of CD10 and low 
levels of CDX expression might be associated with aggressive be-
havior, particularly in hepatoid carcinoma.(24) Others, as previously 
mentioned, proposed that overexpression of c-Met was frequently 
observed in AFP-positive gastric cancer and that this receptor, 
Table 6. Independent prognostic factors of liver metastasis among 
recurred gastric cancer patients in multivariate analysis by the Cox 
proportional hazards model
 HR
95% CI
P-value
Lower Upper
AFP 4.298 1.008 18.325 0.049
Lymphatic invasion 7.330 1.501 35.797 0.014
HR = hazard ratio; 95% CI = 95 percent confi  dence interval; AFP = 
alpha-fetoprotein.AFP Producing Gastric Cancer
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encoded by the c-Met proto-oncogene, regulates cell proliferation 
with its ligand, hepatocyte growth factor (HGF), forming an HGF/
c-Met complex, which was recently found in gastric cancer cells.
(25) Thus, this HGF/c-Met complex could be a clue to the exact 
mechanism of AFP-positive gastric cancer, which might provide 
a solution for the treatment of AFP-positive gastric cancer. With 
regard to treatment, there was a recent report on the inhibition of 
growth and migration of a gastric cancer cell line when treated with 
antisense c-Met oligonucleotides.(25) Far more studies are neces-
sary in order to elucidate the exact mechanism of AFP-producing 
gastric cancer and to optimize treatment.
Because the exact mechanism of liver metastasis in AFP-
positive gastric cancer has not been established, the optimal ap-
proach to treatment remains controversial. Our study showed that 
all AFP-positive gastric cancer patients with liver metastasis died 
within 14 months despite adjuvant treatment. Some authors sug-
gested that percutaneous ethanol injection might be an effective 
treatment for liver metastasis, showing a survival of 18 months, 
which was the longest survival time compared to other treatments, 
including partial resection of the liver and systemic chemotherapy 
(after which all patientsdied within 7 months).(22) Another study 
initially proposed that in cases with liver metastasis, the solitary 
liver metastasis should be resected, and tumor reduction of mul-
tiple liver metastases should be performed, with partial resection of 
liver followed by transarterial continuous-infusion chemotherapy 
for the remnant tumor. However, all these patients died within 8 
months, demonstrating that hepatic resection must be considered 
carefully.(21) Although there are some case reports of successful 
liver resection in AFP-positive gastric cancer with liver metastasis, 
most of these cases are limited to small patient pools. Therefore, 
many more studies with larger patient pools are required regarding 
the treatment of AFP-positive gastric cancer with liver metastasis.
(26,27) 
Depth of invasion, lymph node metastasis and AFP were found 
to be the independent prognostic factors in multivariate analysis, 
with AFP having a hazard ratio of 2.699. This value is a slightly 
low hazard ratio compared to other significant values, thus imply-
ing that AFP might not be a major risk factor in gastric cancer. 
However, when multivariate analysis was limited to gastric cancer 
with liver metastasis, the hazard ratio increased to 4.298, showing 
that AFP could be an important risk factor when liver metastasis 
has occurred. 
AFP-producing gastric cancer is a small subgroup of gastric 
cancer with a high likelihood of rapid metastasis to the liver. Its 
aggressive biological behavior in addition to its unique clinico-
pathological features should be studied further at the cellular and 
molecular levels in order to develop an effective multimodal therapy 
against AFP-producing gastric cancer.
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